Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Ltd is experiencing a significant boost in operational liquidity opportunities due to a remarkable increase in trading volume, reaching $4 billion weekly, which allows management to fortify resources for the continued development of Allocetra. The clinical results from Allocetra have shown statistically significant improvements in pain and function for patients aged 60 and older, further supporting the therapy's therapeutic potential and distinguishing its applicability in the osteoarthritis market. Additionally, the favorable safety profile observed through both three-month and six-month follow-ups enhances the outlook for future studies and potential market expansion of Allocetra’s applications.

Bears say

Enlivex Ltd faces significant risks that contribute to a negative outlook, including the potential for adverse clinical study results and challenges in securing necessary partnerships to advance its applications, which could hinder the approval and market penetration of Allocetra. Furthermore, the volatility and liquidity issues surrounding the RAIN token could undermine its effectiveness as a treasury reserve asset, complicating the financial stability of the company. Additionally, the changing strategy to access capital through digital assets indicates a precarious pivot that may not yield immediate positive results, leading to concerns about long-term viability.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.